Key Takeaways
- Most large commercial insurance plans cover Zepbound for chronic weight management, but coverage requires prior authorization and BMI-based criteria.
- Medicare does not cover Zepbound for weight loss as of April 2026, though coverage for sleep apnea was approved by Medicare for Zepbound in late 2024.
- State Medicaid programs vary widely, with about 13 states covering Zepbound for weight management as of 2026.
- Coverage often requires BMI 30+ (or BMI 27+ with a weight-related condition), documented prior weight loss attempts, and step therapy through cheaper alternatives.
- If Zepbound isn't covered, options include the Eli Lilly LillyDirect program ($349-$499 per month for self-pay vials) or compounded tirzepatide through a state-licensed pharmacy.
Direct answer (40-60 words)
Most large commercial insurance plans cover Zepbound for chronic weight management with prior authorization, including many BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna plans. Coverage usually requires BMI 30+ or BMI 27+ with a weight-related condition. Medicare does not cover Zepbound for weight loss; about 13 state Medicaid programs cover it.
Table of contents
- The 30-second answer
- Commercial insurance coverage by major insurer
- Medicare coverage in 2026
- State Medicaid coverage
- Prior authorization criteria
- Formulary tiers and what they mean for cost
- What to do if your plan denies Zepbound
- LillyDirect self-pay option
- Compounded tirzepatide as an alternative path
- FAQ
- Sources
- Footer disclaimers
Commercial insurance coverage by major insurer
Coverage varies by employer plan and individual policy, but the major commercial insurers have published Zepbound coverage policies. As of April 2026:
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →| Insurer | Typical coverage status | Prior auth required? | Common criteria |
|---|---|---|---|
| BlueCross BlueShield (BCBS) | Covered on most plans | Yes | BMI 30+, or BMI 27+ with weight-related condition |
| UnitedHealthcare (UHC) | Covered on most plans | Yes | BMI 30+, or BMI 27+ with comorbidity, prior weight loss attempt |
| Aetna | Covered on most plans | Yes | BMI 30+, or BMI 27+ with weight-related condition, behavioral counseling documentation |
| Cigna | Covered on most plans | Yes | BMI 30+, or BMI 27+ with comorbidity |
| Kaiser Permanente | Coverage varies by region | Yes | Plan-specific criteria, often includes lifestyle program participation |
| Humana | Covered on commercial plans | Yes | Not covered on Medicare Advantage plans (federal restriction) |
Three caveats apply to this table:
Caveat 1: Self-funded employer plans can carve out GLP-1 coverage. Even if your insurer typically covers Zepbound, your specific employer plan may exclude weight-loss medications. Check your plan's Summary of Benefits and Coverage (SBC).
Caveat 2: Marketplace (ACA) plans tend to have stricter coverage. Lower-tier marketplace plans (bronze, silver) may not cover Zepbound at all, or may put it on a high-cost specialty tier.
Caveat 3: Coverage criteria evolve. Insurance plans update formularies annually (typically January 1). A plan that covered Zepbound this year may add tighter restrictions next year.
The fastest way to verify coverage: log into your insurance member portal, search the formulary for "tirzepatide" or "Zepbound," and read the prior authorization criteria.
Medicare coverage in 2026
Medicare's coverage of Zepbound is limited and condition-specific.
Weight loss alone: Not covered. Medicare Part D excludes weight-loss medications by federal statute (Medicare Modernization Act of 2003). Zepbound prescribed solely for chronic weight management is not eligible for Part D coverage.
Obstructive sleep apnea (OSA): Covered as of 2025. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024 (FDA, 2024). Following that approval, Medicare Part D plans began covering Zepbound for OSA patients who meet specific criteria. Coverage requires:
- Documented diagnosis of moderate-to-severe OSA (apnea-hypopnea index 15+).
- BMI 30 or higher.
- Concurrent use of positive airway pressure (PAP) therapy, or documented PAP intolerance.
- Prior authorization with specific clinical documentation.
Cardiovascular disease: Not yet a Medicare-covered indication for Zepbound. Wegovy (semaglutide) has Medicare coverage for established cardiovascular disease in adults with obesity following its 2024 indication update. Zepbound does not yet have an analogous CV indication.
Medicare beneficiaries who qualify for Zepbound through the OSA pathway typically pay specialty-tier copays of $200 to $500 per month, depending on the plan and coverage gap status. The Eli Lilly Zepbound savings card does not work for Medicare patients.
State Medicaid coverage
State Medicaid programs set their own formularies. Coverage for Zepbound for weight management is fragmented:
States covering Zepbound for weight management (approximate, as of April 2026): California, Connecticut, Delaware, Kansas, Massachusetts, Michigan, Minnesota, New Hampshire, Pennsylvania, Rhode Island, Vermont, Virginia, Wisconsin.
States not covering Zepbound for weight management: the remaining 37 states, though some are reviewing policies.
Even in covering states, prior authorization is required, and criteria typically include BMI thresholds, documented weight-loss attempts, and provider-supervised lifestyle counseling.
A 2024 KFF analysis (Cubanski et al., KFF 2024) found state Medicaid coverage of GLP-1s for obesity has been expanding but remains a minority of states. The financial pressure of widespread coverage is the central barrier.
If your state doesn't cover Zepbound for weight loss, your Medicaid plan may cover it for an FDA-approved use you happen to qualify for (e.g., type 2 diabetes via the Mounjaro brand, or OSA via Zepbound).
Prior authorization criteria
Even when a plan "covers" Zepbound, you usually have to prove medical necessity through prior authorization. The most common criteria across insurers:
BMI threshold. Either BMI 30+ alone, or BMI 27+ with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, OSA, or cardiovascular disease).
Documented weight loss attempts. A history of unsuccessful attempts at lifestyle change (diet, exercise) over 6 to 12 months. Some plans accept self-reported history; others require provider documentation.
Step therapy. A trial of cheaper alternatives first. Some plans require trying generic phentermine, orlistat, or naltrexone-bupropion (Contrave) before approving Zepbound.
Lifestyle counseling. Ongoing engagement with diet, exercise, or behavioral therapy. Documentation usually goes in the PA submission.
Concurrent conditions. For some plans, Zepbound is covered only if you have a specific weight-related condition. BMI 27+ with any qualifying comorbidity opens coverage; isolated obesity at BMI 27-29 does not.
PA approval rates have improved as Zepbound has become more established, but a 2024 GoodRx survey found about 30 to 40% of new GLP-1 PAs are denied on first submission. Most denials are reversible through appeals.
Formulary tiers and what they mean for cost
Even with coverage, your out-of-pocket cost depends on Zepbound's tier on your plan's formulary.
| Formulary tier | What it means | Typical copay |
|---|---|---|
| Tier 2 (preferred brand) | Plan negotiated favorable pricing | $30 to $75 per fill |
| Tier 3 (non-preferred brand) | Standard brand-name placement | $75 to $200 per fill |
| Tier 4 (specialty) | High-cost or injectable medications | 20 to 40% coinsurance, often $200 to $600 per fill |
| Excluded | Plan does not cover this drug | Full cash price applies |
Zepbound most commonly lands on Tier 3 or specialty tier on commercial plans. A handful of large employer plans negotiate Tier 2 placement for Zepbound, particularly those with strong wellness or obesity-management programs.
Deductibles complicate the picture. Most plans require you to meet your annual deductible before the tier copay kicks in. If your deductible is $3,000 and you've spent $0, your first Zepbound fill is full price (about $1,059 cash). After meeting the deductible, the tier copay applies.
The Eli Lilly Zepbound Savings Card can reduce eligible commercial-insurance copays to as low as $25 per fill, with a maximum benefit of about $469 per fill, for up to 13 fills (Eli Lilly, 2026 program terms). Eligibility requires commercial insurance, no government coverage, and an FDA-approved Zepbound indication.
What to do if your plan denies Zepbound
Denial isn't permanent. Three paths back to coverage:
Path 1: Peer-to-peer appeal. Your provider calls the insurance medical director and discusses your case. Approval rates on peer-to-peer appeals run 50 to 70% (Khan et al., Health Affairs 2023).
Path 2: Formal written appeal. If peer-to-peer fails, your provider files a written appeal with additional documentation. Plans must respond within 30 days for standard appeals, 72 hours for urgent.
Path 3: External review. If the formal appeal fails, federal law gives commercial-plan patients the right to an independent external review (Affordable Care Act, Section 2719). The reviewer's decision is binding.
While appeals work through the system, you can pay cash or use one of the alternative paths below.
LillyDirect self-pay option
In late 2024, Eli Lilly launched LillyDirect, a direct-to-patient channel that sells single-dose Zepbound vials at lower prices than retail pharmacy.
Pricing (as of April 2026):
- 2.5 mg single-dose vial (4-week supply): $349
- 5 mg single-dose vial (4-week supply): $499
- Higher doses: $499 to $599 depending on availability
Eligibility:
- Self-pay only. Insurance not used.
- Active Zepbound prescription from a U.S. provider.
- U.S. resident.
- 4-week supply maximum per order.
How it works:
- Your provider sends the prescription to the LillyDirect partner pharmacy.
- You pay self-pay through the LillyDirect portal.
- Vials ship directly to your address in cold-pack packaging.
LillyDirect is meaningfully cheaper than the cash price at retail pharmacies (about $1,059 per month for the same dose). It's not as cheap as compounded tirzepatide, but it's brand-name FDA-approved Zepbound at a self-pay price.
Compounded tirzepatide as an alternative path
If your insurance doesn't cover Zepbound and LillyDirect's price is still too high, compounded tirzepatide is a separate option.
Compounded tirzepatide is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It contains the same active ingredient as Zepbound but is not FDA-approved and is not interchangeable with the brand-name product.
Pricing:
- FormBlends compounded tirzepatide: $179 to $329 per month (no insurance needed).
- Other licensed compounding pharmacies: $200 to $499 per month.
When it makes sense:
- Insurance won't cover Zepbound and you don't want to wait through the appeals process.
- You want predictable monthly pricing without insurance paperwork.
- LillyDirect's price is still beyond what you can sustain.
When brand-name Zepbound makes more sense:
- Your insurance copay (with savings card) is under $100.
- You strongly prefer FDA-approved medications.
- You qualify for LillyDirect and the price works for you.
A licensed clinician should help you weigh the trade-offs. Internal link: see units chart for tirzepatide for compounded dosing math, and why is my compounded semaglutide red for color guidance.
FAQ
What insurance covers Zepbound for weight loss in 2026? Most large commercial insurance plans (BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna) cover Zepbound with prior authorization. Coverage usually requires BMI 30+ or BMI 27+ with a weight-related condition. Self-funded employer plans may exclude GLP-1s entirely.
Does Medicare cover Zepbound? Medicare Part D does not cover Zepbound for weight loss alone (federal statute excludes weight-loss drugs). Medicare does cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, following the December 2024 FDA approval.
Does Medicaid cover Zepbound? About 13 state Medicaid programs cover Zepbound for weight management as of April 2026. Coverage varies and typically requires prior authorization. Most states still don't cover Zepbound for weight loss.
What are the prior authorization requirements for Zepbound? Most plans require BMI 30+ (or BMI 27+ with comorbidity), documented prior weight-loss attempts, and provider-supervised lifestyle counseling. Some plans require step therapy through cheaper weight-loss medications first.
How much does Zepbound cost with insurance? Copays range from $25 (with the Eli Lilly savings card) to over $400 for specialty-tier coinsurance. The most common range is $40 to $200 per fill on covered commercial plans after deductible.
How much does Zepbound cost without insurance? Cash price at major pharmacies runs $1,059 per month. Through LillyDirect (self-pay vials), the price is $349 for 2.5 mg or $499 for 5 mg and above. Compounded tirzepatide at licensed pharmacies starts around $179 per month.
Why did my insurance deny Zepbound? Most denials are because BMI doesn't meet the threshold, prior weight-loss attempts aren't documented, step therapy hasn't been completed, or the prescription is for an off-label use. Your provider's office can file a peer-to-peer or written appeal.
Does the Zepbound savings card work with Medicare? No. Federal anti-kickback rules prohibit drug manufacturers from offering copay assistance to Medicare, Medicaid, TRICARE, or VA patients. Medicare patients pay the plan's specialty-tier coinsurance.
Can I switch from Wegovy to Zepbound on my insurance? Some plans cover both; others prefer one over the other. If your plan covers Wegovy but not Zepbound, switching may require a new prior authorization. Talk to your provider about which medication your plan prefers.
Does my employer plan have to cover Zepbound? No. Self-funded employer plans (used by most large employers) are governed by ERISA and can choose not to cover weight-loss medications. Fully insured employer plans follow state insurance regulations, which generally also don't mandate weight-loss drug coverage.
What's the difference in coverage between Zepbound and Mounjaro? Both are tirzepatide, but they're separate products with separate FDA approvals. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and OSA. Insurance plans cover them for different indications. Your provider must write the prescription for the FDA-approved indication that matches your plan's coverage.
How do I check if my plan covers Zepbound right now? Log into your insurance member portal, search the formulary for "tirzepatide" or "Zepbound," and read the prior authorization criteria. You can also call the member services number on the back of your insurance card and ask about coverage and PA requirements.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
- U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. FDA News Release, December 2024.
- Cubanski J, et al. State Medicaid coverage of weight-loss medications. Kaiser Family Foundation Issue Brief, 2024.
- Khan A, et al. Peer-to-peer appeal outcomes for GLP-1 denials. Health Aff (Millwood). 2023;42(8):1115-1123.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information, revised 2024.
- Eli Lilly. Zepbound Savings Card Terms and Conditions, accessed April 2026.
- Centers for Medicare & Medicaid Services. Part D Drug Coverage Guidance, 2026 plan year.
- Affordable Care Act, Section 2719: Patient Protections - Internal Claims and Appeals and External Review Processes. Public Law 111-148, 2010.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, Kaiser Permanente, and Humana are trademarks of their respective companies. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →